$IPHA

Innate Pharma (IPH) announced that AstraZeneca revised the expected high-level data release from the PACIFIC-9 Phase 3 trial to H1 2027, delayed from H2 2026, due to the study's event-driven nature. Enrollment is complete, according to the company.

Innate Pharma reported Q2 earnings, highlighting a €75 million upfront payment, potential milestones up to €465 million, and tiered royalties. The company expects lacutamab may be included in NCCN guidelines and priced between €500,000 and €625,000 per patient. IPH4502 showed preliminary antitumor activity in advanced solid tumors. Innate plans to present phase I data in November. The company has €21.4 million in cash, excluding a €65 million upfront payment and €28 million from an equity offeri

Innate Pharma reported its first half 2026 results, highlighting a strategic partnership with Sobi for lacutamab, a $75M upfront payment, and a €30M equity financing. Key milestones include the initiation of the TELLOMAK-3 Phase 3 trial for lacutamab, expected to report data in Q1 2027, and the presentation of IPH4502 Phase 1 data at ENA 2026. The company also anticipates a PACIFIC-9 Phase 3 readout for monalizumab by year-end. As of June 30, 2026, Innate Pharma had a cash position of €21.4M and

Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma (IPH, IPHA) announced their strategic partnership is now effective. Sobi will pay Innate $75 million upfront, with potential milestone payments up to $465 million. Innate will conduct a Phase 3 trial for lacutamab, a treatment for cutaneous T-cell lymphoma, with Sobi receiving exclusive commercialization rights.

Innate Pharma (NASDAQ:IPHA) completed enrollment in the dose-escalation portion of its Phase I trial of IPH4502, enrolling 76 patients by July 21. The company expects 10 to 15 patients at go-forward doses across post-PADCEV urothelial cancer, head and neck cancer, and NSCLC, with dose-escalation data later in 2024. Innate also awaits primary-endpoint data from AstraZeneca’s PACIFIC-9 monalizumab study by year-end, after a €30M financing extending its cash runway into 2028.

Innate Pharma SA (Euronext Paris: IPH, Nasdaq: IPHA) announced a proposed private placement offering of about €22.5 million of ordinary shares. Net proceeds will fund continued development of IPH4502, preclinical ADC candidates, and working capital. Cash runway is until end-Q3 2026, or Q3 2027 after a $75m Sobi upfront payment, subject to conditions.

Swedish Orphan Biovitrum (Sobi) and Innate Pharma agreed on a partnership to start the TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma, supporting an accelerated approval filing for lacutamab in Sézary syndrome. Sobi will pay Innate $75m at closing, with up to $40m in milestones, up to $465m for development rights and further milestones, plus tiered double-digit royalties.

Innate Pharma S.A. (IPH.PA) stock is up 8.94% today as traders anticipate its earnings release on March 26, 2026. Key focuses for the earnings call will be updates on Phase III Monalizumab and Phase II Lacutamab clinical programs, cash runway, and potential partnership milestones. Meyka AI gives IPH.PA a "HOLD" rating with an estimated 18.80% upside, but highlights risks such as high debt-to-equity and potential dilution.

Innate Pharma will host a conference call and webcast on Thursday, March 26, 2026, to discuss its financial results for the full year ending December 31, 2025. The event will feature key executives and will be accessible via webcast and telephone. A replay of the webcast will be available on the company's website for 90 days.

After losing some value lately, a hammer chart pattern has been formed for Innate Pharma (IPHA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.